Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients...
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the...
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced...
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer...
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster...
Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune...
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice...
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast...
PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in...
Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platformBria-Pros+ is capable of...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.